Related Experiment Video
Updated: Apr 21, 2026
09:49
In Vitro Assay for Studying the Aggregation of Tau Protein and Drug Screening
Published on: November 20, 2018
21.3K
Invited review: Drug development for tauopathies
1Pharmaceutical Research and Early Development, NORD Disease & Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche AG, CH-4070, Basel, Switzerland.
Neuropathology and Applied Neurobiology
|October 31, 2014
Summary
This review summarizes tauopathy treatments, including clinical candidates like LMTX and AADvac1. Emerging research focuses on tau modifications, expression levels, and cell-to-cell spreading for novel drug development.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Tauopathies are neurodegenerative diseases characterized by abnormal tau protein aggregation.
- Current research explores various therapeutic strategies targeting tau pathology.
Purpose of the Study:
- To review the current status of clinical drug candidates for tauopathies.
- To highlight promising emerging research areas for future tau-targeting therapies.
Main Methods:
- Review of clinical trial data for tau-targeting compounds.
- Analysis of emerging research on tau post-translational modifications, expression, and propagation.
- Comparison of small-molecule and antibody-based therapeutic approaches.
Main Results:
- Several compounds, including LMTX, AADvac1, and ACI-35, are in clinical development.
- Tau post-translational modifications, enzyme targets, and expression modulation offer therapeutic potential.
- Prion-like tau spreading presents a novel target for drug development.
Conclusions:
- Modulating tau pathology through various strategies shows promise for treating tauopathies.
- Development of effective clinical biomarkers, such as PET imaging, is crucial for advancing drug development.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
01:23Alzheimer Disease ll: Pathophysiology
7
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and...
7